Cargando…
First Report of Severe Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplant in a Patient With Myelodysplastic Syndrome Treated With Atezolizumab: Literature Review
Checkpoint inhibitors have become a widely used and available immunotherapy option for treating a variety of malignancies, including hematological malignancies. Patients receiving these therapies may go on to receive a curative allogeneic hematopoietic stem cell transplant (allo-HSCT). This presents...
Autores principales: | Hsiao, Mindy, Tatishchev, Sergei, Khedro, Tarek, Yaghmour, Bassam, O’Connell, Casey, Yaghmour, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239570/ https://www.ncbi.nlm.nih.gov/pubmed/32494318 http://dx.doi.org/10.14740/wjon1263 |
Ejemplares similares
-
Midostaurin-Related Interstitial Lung Injury in FLT3(+) Acute Myeloid Leukemia Post-Allogeneic Transplant
por: Vaidya, Poorva, et al.
Publicado: (2019) -
Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors
por: Hagiya, Ashley, et al.
Publicado: (2019) -
The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant
por: Li, Grace Xiuqing, et al.
Publicado: (2018) -
Minimal Change Disease Secondary to Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndrome
por: Elghawy, Omar, et al.
Publicado: (2022) -
Graft-versus-host disease in allogeneic transplantation: the good and the bad
por: Kröger, Nicolaus-Martin
Publicado: (2022)